english.prescrire.org > Spotlight > 100 most recent > Prescrire's ratings of new drugs in 2024

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's ratings of new drugs in 2024

 Marketing Authorisations  One major therapeutic advance, a few practical advances for children, but otherwise many new products or indications of little value this year.
Full article available for download (FREE)

Prescrire’s ratings of new products and indications over the past 10 years
 
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Bravo  BRAVO
0 0 0 0 0 1 0 0 0 0
A Real Advance  A REAL ADVANCE
3 1 1 2 1 2 3 0 0 0
Offers an advantage  OFFERS AN ADVANTAGE
5 5 9 11 10 6 14 11 10 6
Possibly helpful  POSSIBLY HELPFUL 
15 9 18 22 13 18 19 23 20 23
Nothing new  NOTHING NEW
43 56 45 50 61 55 51 63 73 60
Judgement reserved  JUDGEMENT RESERVED
6 5 4 5 9 17 12 13 10 14
Not acceptable  NOT ACCEPTABLE 
15 16 15 9 14 10 9 14 8 18
TOTAL 87 92 92 99 108 109 108 124 121 122
 
 
Therapeutic advances 2012-2021
 

 ©Prescrire 1 April 2025

Source: "Prescrire's ratings of new drugs in 2024: a brief review" Prescrire Int 2025; 34 (269): 102-104. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:

"Towards better patient care:
drugs to avoid in 2025"
Prescrire Int 2025;
34 (267): 52-55 (full version: 11 pages).
FREE
 

"Prescrire's ratings of new
drugs in 2023: a brief review"
Prescrire Int 2024;
33 (258): 100-102.
FREE

 

Read more:

This month's contents

All the subjects in
Prescrire's spotlight